U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT06804590) titled 'A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis' on Dec. 09, 2024.
Brief Summary: This study is a multicenter, randomized, double-blinded, parallel-group Phase III clinical study to compare the clinical efficacy, safety, and immunogenicity of 9MW0311 and Prolia(R) in Chinese postmenopausal women with osteoporosis at high risk for fracture.
Study Start Date: Nov. 16, 2024
Study Type: INTERVENTIONAL
Condition:
Postmenopausal Women Osteoporosis
Intervention:
DRUG: 9MW0311
9MW0311 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 co...